Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market

FREMONT, Calif.: FREMONT, Calif., Sept. 8, 2021 /PRNewswire/ -- Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, announced today that it has closed its $80 million Series B financing round, bringing its total funding to $110 million. The Series...

Click to view original post